Skip to main content

. 1984 Dec;18(6):965–967. doi: 10.1111/j.1365-2125.1984.tb02573.x

Adverse effects from metoprolol are not generally associated with oxidation status.

D W Clark, A K Morgan, H Waal-Manning

PMCID: PMC1463667 PMID: 6335664

965

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Eichelbaum M., Bertilsson L., Säwe J. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol. 1983 Mar;15(3):317–321. doi: 10.1111/j.1365-2125.1983.tb01505.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
Idle J. R., Oates N. S., Shah R. R., Smith R. L. Protecting poor metabolizers, a group at high risk of adverse drug reactions. Lancet. 1983 Jun 18;1(8338):1388–1388. doi: 10.1016/s0140-6736(83)92172-4. [DOI] [PubMed] [Google Scholar]
Lennard M. S., Silas J. H., Freestone S., Ramsay L. E., Tucker G. T., Woods H. F. Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560. doi: 10.1056/NEJM198212163072505. [DOI] [PubMed] [Google Scholar]
Lennard M. S., Silas J. H., Freestone S., Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1982 Aug;14(2):301–303. doi: 10.1111/j.1365-2125.1982.tb01982.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Shah R. R., Oates N. S., Idle J. R., Smith R. L., Lockhart J. D. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):295–299. doi: 10.1136/bmj.284.6312.295. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES